Veru Inc.

Veru is a biopharmaceutical company focused on urology and oncology. Veru utilizes FDA’s 505(b)(2) regulatory approval pathway to develop and commercialize drug candidates. FDA’s 505(b)(2) regulatory approval pathway is designed to allow for potentially expedited regulatory approval based on a previously established safety and efficacy profile of the product. Veru is developing products under the 505(b)(1) pathway as well, which is the traditional new drug application (NDA) pathway. The company is currently developing drug product candidates for benign prostatic hyperplasia (BPH or enlarged prostate), hot flashes associated with prostate cancer hormone treatment, male infertility and novel oral chemotherapy (alpha & beta tubulin inhibitor) for a variety of malignancies, including metastatic prostate, breast and ovarian cancers.

Bank Name Veru Inc.
Stock Exchange NASDAQ
Symbol VERU
Sector Healthcare
Industry Specialty Chemicals
Country United States
World Region Amarica
Chairman
CEO Dr. Mitchell S. Steiner
Employees 175
Website www.veruhealthcare.com
Registered Year 1896

 

UpdateContent
UpdateContent
UpdateContent